ACC pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
21 of 23 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
AstraZeneca 1
No dated milestone in 2025 to 2030
Ayala Pharmaceuticals 1
No dated milestone in 2025 to 2030
Cellestia Biotech 1
CB-103Phase 1/2
No dated milestone in 2025 to 2030
Dana-Farber Cancer Institute 1
IvonescimabPhase 2
No dated milestone in 2025 to 2030
Eisai (investigator studies) 1
Lenvatinib (off Label)Phase 2
No dated milestone in 2025 to 2030
Elevar Therapeutics 1
RivoceranibTrials stopped
No dated milestone in 2025 to 2030
Exelixis 1
ZanzalintinibPhase 2
No dated milestone in 2025 to 2030
Eye and ENT Hospital of Fudan University 1
No dated milestone in 2025 to 2030
HitGen 1
HG146Phase 2
No dated milestone in 2025 to 2030
Memorial Sloan Kettering 1
Enfortumab VedotinPhase 2
No dated milestone in 2025 to 2030
Memorial Sloan Kettering (investigator) 1
Regorafenib (off Label)Phase 2
No dated milestone in 2025 to 2030
National Cancer Centre Singapore 1
No dated milestone in 2025 to 2030
National Cancer Institute 1
SX-682 + DocetaxelPhase 1/2
No dated milestone in 2025 to 2030
Pfizer 1
Axitinib (off Label)Phase 2
No dated milestone in 2025 to 2030
Radboud UMC; Johns Hopkins (investigators) 1
No dated milestone in 2025 to 2030
Remix Therapeutics (merging with Passage Bio) 1
REM-422Phase 1/2
No dated milestone in 2025 to 2030
Servier (registry sponsor Day One Biopharmaceuticals) 1
EMBLEM-1 first patients dosed, Oct 19, 2026
Shanghai Ninth People's Hospital 1
ApatinibPhase 2
No dated milestone in 2025 to 2030
Trisha Wise-Draper (investigator) 1
AmivantamabPhase 2
No dated milestone in 2025 to 2030
University of Michigan 1
APG-115 (alrizomadlin)Phase 1/2
No dated milestone in 2025 to 2030
VM Oncology 1
VMD-928Phase 1/2
No dated milestone in 2025 to 2030